Skip to main content
Fig. 3 | Cancer Nanotechnology

Fig. 3

From: Low-dose pleiotropic radiosensitive nanoformulations for three-pronged radiochemotherapy of hypoxic brain glioblastoma under BOLD/DWI monitoring

Fig. 3

Therapeutic response of the two most common GBM cell lines U87MG and U251 to low-dose pleiotropic hypoxic radiosensitive nanoformulation. A The illustration shows journal articles searched from the Web of Science in the last 3 years (2020–2022) to identify cell lines for nanoparticle-based RT of GBM. BD The difference between U87 MG and U251 cells on this multi-effect synergistic effect of SLC-AN/SN@AQ NPs under radiation was evaluated by the following ratios calculated under normoxic and hypoxic conditions, including B survival fraction (SF) using colony formation assay, C potential DNA damage represented by tail length (TL) using the comet assay, and D cell death represented by relative PI level using Calcein-AM/PI dual staining

Back to article page